3-Hydroxypyridinone derivatives as metal-sequestering agents for therapeutic use. (Q38397352)

2 September 2017

1 reference

title

3-Hydroxypyridinone derivatives as metal-sequestering agents for therapeutic use. (English)

1 reference

2 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25826364%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

M Amélia Santos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25826364%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

1 January 2015

1 reference

Future Medicinal Chemistry

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25826364%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25826364%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25826364%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

383-410

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25826364%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology of haemoglobin disorders and derived service indicators

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Superoxide and nitric oxide in pathological conditions associated with iron overload: the effects of antioxidants and chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Body iron metabolism and pathophysiology of iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Iron chelators can protect against oxidative stress through ferryl heme reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Liver iron concentrations and urinary hepcidin in beta-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Renal aspects of thalassaemia a changing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

A narrative review of peri-operative management of patients with thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Human exposure to aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

The interactions between the chronic exposure to Aluminum and liver regeneration on bile flow and organic anion transport in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Redox cycling of iron by Abeta42.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Pro-oxidant effects in the brain of rats concurrently exposed to uranium and stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Combined action of uranium and stress in the rat. II. Effects on male reproduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Rational design of sequestering agents for plutonium and other actinides.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Hard and Soft Acids and Bases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Iron chelation, quo vadis?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Hydroxypyri(mi)dine-based chelators as antidotes of toxicity due to aluminum and actinides

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

A family of hydroxypyrone ligands designed and synthesized as iron chelators.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Searching for new aluminium chelating agents: a family of hydroxypyrone ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Thermodynamic remarks on chelating ligands for aluminium related diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Ferric complexes of 3-hydroxy-4-pyridinones characterized by density functional theory and Raman and UV-vis spectroscopies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Aluminium distribution and excretion: a comparative study of a number of chelating agents in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

A bis(3-hydroxy-4-pyridinone)-EDTA derivative as a strong chelator for M3+ hard metal ions: complexation ability and selectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinone

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

New tris(hydroxypyridinones) as iron and aluminium sequestering agents: synthesis, complexation and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

N-Carboxyalkyl derivatives of 3-hydroxy-4-pyridinones: synthesis, complexation with Fe(III), Al(III) and Ga(III) and in vivo evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Bifunctional 3-hydroxy-4-pyridinone derivatives as potential pharmaceuticals: synthesis, complexation with Fe(III), Al(III) and Ga(III) and in vivo evaluation with 67Ga

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Alkylaryl-amino derivatives of 3-hydroxy-4-pyridinones as aluminium chelating agents with potential clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: solution and biodistribution studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

N-Arylamine derivatives of 3-hydroxy-4-pyridinones: solution studies and bioevaluation in view of Al-detoxification roles

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Advances in iron chelation: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Amido-3-hydroxypyridin-4-ones as iron(III) ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Toward optimized high-relaxivity MRI agents: the effect of ligand basicity on the thermodynamic stability of hexadentate hydroxypyridonate/catecholate gadolinium(III) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

A new bis(3-hydroxy-4-pyridinone)-IDA derivative as a potential therapeutic chelating agent. Synthesis, metal-complexation and biological assays

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Combined chelation of bi-functional bis-hydroxypiridinone and mono-hydroxypiridinone: synthesis, solution and in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

New tripodal hydroxypyridinone based chelating agents for Fe(III), Al(III) and Ga(III): Synthesis, physico-chemical properties and bioevaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Synthesis and iron(III)-chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing copolymers

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Combined iron chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Thorium(IV) Complexes of Bidentate Hydroxypyridinonates1

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO).

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Designing the ideal uranyl ligand: a sterically induced speciation change in complexes with thiophene-bridged bis(3-hydroxy-n-methylpyridin-2-one).

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Influence of linker geometry on uranyl complexation by rigidly linked bis(3-hydroxy-N-methyl-pyridin-2-one).

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Plutonium(IV) sequestration: structural and thermodynamic evaluation of the extraordinarily stable cerium(IV) hydroxypyridinonate complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

3,4,3-LI(1,2-HOPO): in vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Hexadentate terephthalamide(bis-hydroxypyridinone) ligands for uranyl chelation: structural and thermodynamic consequences of ligand variation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Synthetic approaches to mixed ligand chelators on t-butylphenol-formaldehyde oligomer (PFO) platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Synthesis and intestinal transport of the iron chelator maltosine in free and dipeptide form.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

New silica-immobilized hydroxypyrimidinone as sorbent of hard metal ions from aqueous fluids.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Incorporation of hydroxypyridinone ligands into self-assembled monolayers on mesoporous supports for selective actinide sequestration

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Functional sorbents for selective capture of plutonium, americium, uranium, and thorium in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Iron binding dendrimers: a novel approach for the treatment of haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Design of clinically useful macromolecular iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Nanoparticles in cellular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Nanoparticulate systems for brain delivery of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Brain iron metabolism: neurobiology and neurochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

The relevance of iron in the pathogenesis of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Designing multiple ligands - medicinal chemistry strategies and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

A small molecule targeting the multifactorial nature of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Multi-target-directed ligands to combat neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chlo

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Chelation therapy for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Novel drug targets based on metallobiology of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Metal complexes of maltol and close analogues in medicinal inorganic chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Synthesis of feralex a novel aluminum/iron chelating compound

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

In vitro studies of 3-hydroxy-4-pyridinones and their glycosylated derivatives as potential agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Multifunctional iron-chelators with protective roles against neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

New hydroxypyridinone iron-chelators as potential anti-neurodegenerative drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Identifying chelators for metalloprotein inhibitors using a fragment-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Design and therapeutic application of matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Zinc-binding groups modulate selective inhibition of MMPs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Utilization of microbial iron assimilation processes for the development of new antibiotics and inspiration for the design of new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Iron chelation therapy for malaria: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Synthesis, antimicrobial evaluation and QSAR study of some 3-hydroxypyridine-4-one and 3-hydroxypyran-4-one derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Identification of a new hexadentate iron chelator capable of restricting the intramacrophagic growth of Mycobacterium avium

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Fluorescent 3-hydroxy-4-pyridinone hexadentate iron chelators: intracellular distribution and the relevance to antimycobacterial properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Deferoxamine inhibition of malaria is independent of host iron status

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Basic 3-hydroxypyridin-4-ones: potential antimalarial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162

PREVENTION AND TREATMENT OF ALUMINUM TOXICITY INCLUDING CHELATION THERAPY: STATUS AND RESEARCH NEEDS

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.14.162